TD Cowen lowered the firm’s price target on Procept BioRobotics (PRCT) to $85 from $99 and keeps a Buy rating on the shares. The firm notes sales topped estimates as the Hydros rollout continues and guidance met expectations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Strong Growth Potential for PROCEPT BioRobotics Amid Market Challenges
- Procept BioRobotics price target lowered to $95 from $105 at Morgan Stanley
- Procept BioRobotics price target lowered to $90 from $105 at Truist
- Positive Outlook for PROCEPT BioRobotics: Resilience and Growth Opportunities Justify Buy Rating
- PROCEPT BioRobotics Reports Strong 2024 Growth